Business & Economy
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Source: Business News · Published
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Related stories
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
Business News ·
People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
The data on Novo's Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.
Business News ·
Greggs to shut four factories and cut 740 jobs
The company says it needs to "keep evolving alongside changing customer expectations".
feeds.bbci.co.uk ·
Economic growth in UK and US revised higher; diesel on brink of £2 a litre for first time – business live
Second-quarter GDP growth on both sides of the Atlantic was stronger than first estimated This morning’s upgrade to UK growth in April-June is a boost to Andy Burnham, analysts say, even though he didn’t take office until almost a month later. Chris Beauchamp , chief market analy
Business | The Guardian ·
Stellantis CEO reconfirms 2026 guidance, says turnaround plan continues as automaker's shares hit new low
Stellantis CEO Antonio Filosa on Wednesday reconfirmed the company's 2026 guidance and its plans to be cash-flow positive by 2027.
Business News ·